ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. founded in 2015 and is based in Winston-Salem, North Carolina.

ProKidney Corp.

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s sh...

Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)

Prokidney Corp. (($PROK)) announced an update on their ongoing clinical study. Prokidney Corp. is currently conducting a clinical study titled ‘A P...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PROK	$2.19	+4.78%	1.53M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PROK	$2.19	+4.8%	1.53M
3
4
5
6

PROK

PROK

Dividend Overview

Get ProKidney Corp. Data in Excel

Get ProKidney Corp. Data in Excel